智利胃癌治疗市场,按类型(腺癌、胃肠道间质瘤、类癌瘤、淋巴瘤等)、分期(III 期、II 期、IV 期、I 期等)、治疗(化疗、靶向治疗、免疫检查点抑制剂等)、给药途径(肠胃外、口服等)、最终用户(医院、专科诊所、研究和学术机构等)、分销渠道(医院药房、零售药房等)划分。行业趋势和预测至 2029 年。
市场分析与洞察:智利胃癌治疗市场
智利胃癌治疗市场预计将在 2022 年至 2029 年的预测期内获得显着增长。Data Bridge Market Research 分析称,在 2022 年至 2029 年的预测期内,该市场以 7.7% 的复合年增长率增长,预计到 2029 年将达到 2375 万美元。胃肠道肿瘤、淋巴瘤和腺癌病例的增加增加了对药物和治疗的需求,预计将推动胃癌治疗市场的增长。
胃癌是一种在胃壁中形成恶性(癌)细胞的疾病。年龄、饮食和胃病会影响患上胃癌的风险。胃癌的症状包括消化不良和胃部不适或疼痛。
胃壁由五层组织组成。从最内层到最外层,胃壁的各层为:粘膜、粘膜下层、肌肉、浆膜下层(结缔组织)和浆膜。胃癌始于粘膜,并随着生长扩散到外层。胃癌往往在多年内缓慢发展。在真正的癌症发展之前,胃内壁(粘膜)通常会在癌症完全发展之前发生癌前病变。这些早期变化很少引起症状,因此经常无法被发现。癌症在胃的不同部位发展会引起不同的症状,并且往往会有不同的结果。癌症的位置也会影响治疗方案。
预计胃癌发病率的上升和医疗保健支出的增加将推动智利整个市场的增长。
智利胃癌治疗 市场范围和市场规模
智利胃癌治疗市场根据类型、阶段、治疗、给药途径、最终用户和分销渠道进行细分。细分市场之间的增长有助于您分析利基增长领域和进入市场的策略,并确定您的核心应用领域和目标市场的差异。
- 根据类型,智利胃癌治疗市场分为腺癌、胃肠道间质瘤、类癌瘤、淋巴瘤等。2021 年,由于智利这种特定胃癌类型的患病率不断上升,预计腺癌领域将占据市场主导地位。
- 根据分期,智利胃癌治疗市场分为 III 期、II 期、IV 期、I 期和其他阶段。预计 2022 年 III 期将占据市场主导地位,因为该阶段的药物消耗量很高。
- 根据治疗方法,智利胃癌治疗市场分为化疗、靶向治疗、免疫检查点抑制剂等。2022 年,化疗领域预计将占据市场主导地位,因为这种治疗方式具有较高的总体生存率和较低的胃癌复发率。
- 根据给药途径,智利胃癌治疗市场分为肠外给药、口服给药和其他给药方式。预计 2022 年肠外给药将占据市场主导地位,因为它是治疗癌症最有效的方法。此外,各种治疗方法都以注射形式提供。
- 根据最终用户,智利胃癌治疗市场分为医院、专科诊所、研究和学术机构等。2022 年,医院部门预计将占据市场主导地位,因为它为患者提供最好的医疗服务。由于患者对医疗保健的关注度不断提高,发达国家和发展中国家的医院对晚期癌症治疗的需求很高。
- 根据分销渠道,智利胃癌治疗市场分为医院药房、零售药房和其他。2022 年,医院药房预计将占据市场主导地位,因为它们是肿瘤学家推荐用于胃癌治疗和品牌满意度的各种药物的主要来源。
智利胃癌治疗市场国家级分析
对智利胃癌治疗市场进行了分析,并按上述类型、阶段、治疗、给药途径、最终用户和分销渠道提供了市场规模信息。
智利胃癌治疗市场报告涵盖的国家是智利。
由于药品审批不断增加,且能够作为独立药物使用(尤其是在某些阶段),预计智利的靶向产品领域将在 2022 年至 2029 年的预测期内实现最高增长率。
报告的国家部分还提供了影响单个市场因素和国内市场监管变化,这些因素和变化影响了市场的当前和未来趋势。新销售、替代销售、国家人口统计、监管法案和进出口关税等数据点是用于预测单个国家市场情景的一些主要指标。此外,在提供国家数据的预测分析时,还考虑了智利品牌的存在和可用性以及由于来自本地和国内品牌的激烈或稀少的竞争而面临的挑战、销售渠道的影响。
主要市场参与者不断增加的战略活动增强了人们对胃癌的认识,从而推动了市场的增长
智利胃癌治疗市场还为您提供特定市场中每个国家增长的详细市场分析。此外,它还提供有关市场参与者的战略及其地理分布的详细信息。数据适用于 2020 年至 2029 年期间。
竞争格局和智利胃癌治疗市场份额分析
智利胃癌治疗市场竞争格局按竞争对手提供详细信息。详细信息包括公司概况、公司财务状况、收入、市场潜力、研发投资、新市场计划、生产基地和设施、公司优势和劣势、产品发布、产品试验渠道、产品批准、专利、产品宽度和广度、应用优势和技术生命线曲线。以上提供的数据点仅与公司对智利胃癌治疗市场的关注有关
在智利胃癌治疗市场开展业务的一些主要公司包括辉瑞公司、默克公司、Celnova Pharma、Teva Pharmaceutical Industries Limited、阿斯利康、百时美施贵宝公司、赛诺菲、Laboratorio Varifarma SA、Tecnofarma SA、F. Hoffmann-La Roche Ltd.、Biotoscana Group、Megalabs Chile SA 等。DBMR 分析师了解竞争优势,并为每个竞争对手分别提供竞争分析。
世界各地的公司也签订了各种合同和协议,进一步加速了智利胃癌治疗市场的增长。
例如,
- 2020年5月,礼来公司宣布,美国食品药品监督管理局(FDA)已批准CYRAMZA®(雷莫芦单抗注射液,10 mg/mL溶液)与厄洛替尼联合用于一线治疗表皮生长因子受体(EGFR)外显子19缺失或外显子21(L858R)突变的转移性非小细胞肺癌(NSCLC)。凭借此项批准,CYRAMZA现已获得六项FDA批准,用于治疗某些类型的肺癌、肝癌、胃癌和结直肠癌。该公司的此次新药批准增加了其在市场上的销量和需求,从而导致未来销量增加。
- 2019 年 11 月,辉瑞公司宣布其 Upjohn 部门与 Mylan NV 合并,成立了一家名为 Viatris 的新公司。该公司业务部门与 Mylan NV 的合并增加了其产品组合,从而增加了市场对其产品的需求
SKU-
Get online access to the report on the World's First Market Intelligence Cloud
- Interactive Data Analysis Dashboard
- Company Analysis Dashboard for high growth potential opportunities
- Research Analyst Access for customization & queries
- Competitor Analysis with Interactive dashboard
- Latest News, Updates & Trend analysis
- Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
目录
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF CHILE GASTRIC CANCER TREATMENT MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.7 MULTIVARIATE MODELLING
2.8 TYPE LIFELINE CURVE
2.9 DBMR MARKET POSITION GRID
2.1 VENDOR SHARE ANALYSIS
2.11 MARKET END USER COVERAGE GRID
2.12 SECONDARY SOURCES
2.13 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PESTEL'S MODEL
4.2 PORTER'S 5 FORCES
5 EPIDEMIOLOGY
6 PIPELINE ANALYSIS FOR CHILE GASTRIC CANCER TREATMENT MARKET
7 SUMMARY WRITE-UP, CHILE
7.1 OVERVIEW
8 CHILE GASTRIC CANCER TREATMENT MARKET: REGULATORY SCENARIO
9 MARKET OVERVIEW
9.1 DRIVERS
9.1.1 INCREASE IN INCIDENCE OF GASTROINTESTINAL TUMORS, LYMPHOMA, AND ADENOCARCINOMA
9.1.2 RISE IN ALCOHOL CONSUMPTION AND SURGE IN SMOKING
9.1.3 HEALTH SYSTEM OF CHILE
9.1.4 HIGH PREVALENCE OF OBESITY
9.1.5 RECENT ADVANCEMENTS IN GASTRIC CANCER TREATMENT
9.2 RESTRAINTS
9.2.1 COMMERCIALIZATION OF PHARMACEUTICALS IN CHILE
9.2.2 HIGH COST OF TESTING AND MEDICATIONS
9.2.3 ADVERSE SIDE-EFFECTS OF GASTRIC CANCER TREATMENT
9.3 OPPORTUNITIES
9.3.1 INCREASING DRUG APPROVALS
9.3.2 GOVERNMENT INITIATIVES FOR CANCER CARE
9.3.3 PARTNERSHIP AND AGREEMENT BY MAJOR PLAYERS
9.4 CHALLENGES
9.4.1 CHALLENGE RELATED TO HEALTHCARE PROFESSIONALS
9.4.2 ALTERNATIVE GASTRIC CANCER THERAPIES
10 IMPACT OF COVID-19 PANDEMIC ON CHILE GASTRIC CANCER TREATMENT MARKET
10.1 PRICE IMPACT
10.2 IMPACT ON DEMAND
10.3 IMPACT ON SUPPLY CHAIN
10.4 STRATEGIC DECISIONS FOR MANUFACTURERS
10.5 CONCLUSION
11 CHILE GASTRIC CANCER TREATMENT MARKET, BY TYPE
11.1 OVERVIEW
11.2 ADENOCARCINOMA
11.3 GASTROINTESTINAL STROMAL TUMOR
11.4 CARCINOID TUMOR
11.5 LYMPHOMA
11.6 OTHERS
12 CHILE GASTRIC CANCER TREATMENT MARKET, BY STAGES
12.1 OVERVIEW
12.2 STAGE III
12.3 STAGE II
12.4 STAGE IV
12.5 STAGE I
12.6 OTHERS
13 CHILE GASTRIC CANCER TREATMENT MARKET, BY TREATMENT
13.1 OVERVIEW
13.2 CHEMOTHERAPY
13.2.1 FLUOROURACIL
13.2.2 OXALIPLATIN
13.2.3 CISPLATIN
13.2.4 DOCETAXEL
13.2.5 PACLITAXEL
13.2.6 IRINOTECAN
13.2.7 CAPECITABINE
13.2.8 CARBOPLATIN
13.2.9 EPIRUBICIN
13.2.10 OTHERS
13.3 TARGETED THERAPY
13.3.1 MONOCLONAL ANTIBODY THERAPY
13.3.1.1 trastuzumab (herceptin)
13.3.1.2 ramucirumab
13.3.2 MULTIKINASE INHIBITORS
13.3.2.1 Sunitinib
13.3.2.2 Regorafenib
13.4 IMMUNE CHECKPOINT INHIBITORS
13.5 OTHERS
14 CHILE GASTRIC CANCER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION
14.1 OVERVIEW
14.2 PARENTERAL
14.2.1 INTRAVENOUS
14.2.2 SUBCUTANEOUS
14.2.3 OTHERS
14.3 ORAL
14.3.1 TABLET
14.3.2 CAPSULE
14.3.3 OTHERS
14.4 OTHERS
15 CHILE GASTRIC CANCER TREATMENT MARKET, BY END USERS
15.1 OVERVIEW
15.2 HOSPITALS
15.3 SPECIALITY CLINICS
15.4 RESEARCH & ACADEMIC INSTITUTES
15.5 OTHERS
16 CHILE GASTRIC CANCER TREATMENT MARKET, BY DISTRIBUTION CHANNEL
16.1 OVERVIEW
16.2 HOSPITAL PHARMACY
16.3 RETAIL PHARMACY
16.4 OTHERS
17 CHILE GASTRIC CANCER TREATMENT MARKET: COMPANY LANDSCAPE
17.1 COMPANY SHARE ANALYSIS: CHILE GASTRIC CANCER TREATMENT MARKET
18 SWOT ANALYSIS
19 COMPANY PROFILE
19.1 MERCK KGAA
19.1.1 COMPANY SNAPSHOT
19.1.2 REVENUE ANALYSIS
19.1.3 PRODUCT PORTFOLIO
19.1.4 RECENT DEVELOPMENTS
19.2 F.HOFFMAN-LA ROCHE LTD
19.2.1 COMPANY SNAPSHOT
19.2.2 REVENUE ANALYSIS
19.2.3 PRODUCT PORTFOLIO
19.2.4 RECENT DEVELOPMENT
19.3 TEVA PHARMACEUTICAL INDUSTRIES LTD
19.3.1 COMPANY SNAPSHOT
19.3.2 REVENUE ANALYSIS
19.3.3 PRODUCT PORTFOLIO
19.3.4 RECENT DEVELOPMENT
19.4 ASTRAZENECA
19.4.1 COMPANY SNAPSHOT
19.4.2 REVENUE ANALYSIS
19.4.3 PRODUCT PORTFOLIO
19.4.4 RECENT DEVELOPMENTS
19.5 SANOFI
19.5.1 COMPANY SNAPSHOT
19.5.2 REVENUE ANALYSIS
19.5.3 PRODUCT PORTFOLIO
19.5.4 RECENT DEVELOPMENTS
19.6 MEGALABS CHILE S.A.
19.6.1 COMPANY SNAPSHOT
19.6.2 PRODUCT PORTFOLIO
19.6.3 RECENT DEVELOPMENT
19.7 BRISTOL-MYERS SQUIBB COMPANY
19.7.1 COMPANY SNAPSHOT
19.7.2 REVENUE ANALYSIS
19.7.3 PRODUCT PORTFOLIO
19.7.4 RECENT DEVELOPMENTS
19.8 CELNOVA PHARMA
19.8.1 COMPANY SNAPSHOT
19.8.2 PRODUCT PORTFOLIO
19.8.3 RECENT DEVELOPMENT
19.9 GRUPO BIOTOSCANA
19.9.1 COMPANY SNAPSHOT
19.9.2 REVENUE ANALYSIS
19.9.3 PRODUCT PORTFOLIO
19.9.4 RECENT DEVELOPMENT
19.1 LABORATORI VARIFARMA S.A.
19.10.1 COMPANY SNAPSHOT
19.10.2 PRODUCT PORTFOLIO
19.10.3 RECENT DEVELOPMENT
19.11 NOVARTIS AG
19.11.1 COMPANY SNAPSHOT
19.11.2 REVENUE ANALYSIS
19.11.3 PRODUCT PORTFOLIO
19.11.4 RECENT DEVELOPMENT
19.12 PFIZER INC.
19.12.1 COMPANY SNAPSHOT
19.12.2 REVENUE ANALYSIS
19.12.3 PRODUCT PORTFOLIO
19.12.4 RECENT DEVELOPMENTS
19.13 TECNOFARMA S.A.
19.13.1 COMPANY SNAPSHOT
19.13.2 PRODUCT PORTFOLIO
19.13.3 RECENT DEVELOPMENT
20 QUESTIONNAIRE
21 RELATED REPORTS
表格列表
TABLE 1 CHILE GASTRIC CANCER TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 2 CHILE GASTRIC CANCER TREATMENT MARKET, BY STAGES, 2020-2029 (USD MILLION)
TABLE 3 CHILE GASTRIC CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 4 CHILE CHEMOTHERAPY IN GASTRIC CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 5 CHILE TARGETED THERAPY IN GASTRIC CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 6 CHILE MONOCLONAL ANTIBODY THERAPY IN GASTRIC CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 7 CHILE MULTIKINASE INHIBITORS IN GASTRIC CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 8 CHILE GASTRIC CANCER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 9 CHILE PARENTERAL IN GASTRIC CANCER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 10 CHILE ORAL IN GASTRIC CANCER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 11 CHILE GASTRIC CANCER TREATMENT MARKET, BY END USERS, 2020-2029 (USD MILLION)
TABLE 12 CHILE GASTRIC CANCER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
图片列表
FIGURE 1 CHILE GASTRIC CANCER TREATMENT MARKET: SEGMENTATION
FIGURE 2 CHILE GASTRIC CANCER TREATMENT MARKET: DATA TRIANGULATION
FIGURE 3 CHILE GASTRIC CANCER TREATMENT MARKET: DROC ANALYSIS
FIGURE 4 CHILE GASTRIC CANCER TREATMENT MARKET: COUNTRY VS REGIONAL MARKET ANALYSIS
FIGURE 5 CHILE GASTRIC CANCER TREATMENT MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 CHILE GASTRIC CANCER TREATMENT MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 CHILE GASTRIC CANCER TREATMENT MARKET: MULTIVARIATE MODELLING
FIGURE 8 CHILE GASTRIC CANCER TREATMENT MARKET: DBMR MARKET POSITION GRID
FIGURE 9 CHILE GASTRIC CANCER TREATMENT MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 CHILE GASTRIC CANCER TREATMENT MARKET: END USER OVERAGE GRID
FIGURE 11 CHILE GASTRIC CANCER TREATMENT MARKET: SEGMENTATION
FIGURE 12 INCREASE IN INCIDENCE OF GASTROINTESTINAL TUMORS, LYMPHOMA, ADENOCARCINOMA, AND HIGH PREVALENCE OF OBESITY ARE EXPECTED TO DRIVE THE CHILE GASTRIC CANCER TREATMENT MARKET IN THE FORECAST PERIOD
FIGURE 13 ADENOCARCINOMA SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE CHILE GASTRIC CANCER TREATMENT MARKET IN 2022 & 2029
FIGURE 14 REGULATORY PROCESS OF DRUGS AND BIOLOGICS APPROVAL IN CHILE
FIGURE 15 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF CHILE GASTRIC CANCER TREATMENT MARKET
FIGURE 16 CHILE GASTRIC CANCER TREATMENT MARKET: BY TYPE, 2021
FIGURE 17 CHILE GASTRIC CANCER TREATMENT MARKET: BY TYPE, 2020-2029 (USD MILLION)
FIGURE 18 CHILE GASTRIC CANCER TREATMENT MARKET: BY TYPE, CAGR (2022-2029)
FIGURE 19 CHILE GASTRIC CANCER TREATMENT MARKET: BY TYPE, LIFELINE CURVE
FIGURE 20 CHILE GASTRIC CANCER TREATMENT MARKET: BY STAGES, 2021
FIGURE 21 CHILE GASTRIC CANCER TREATMENT MARKET: BY STAGES, 2020-2029 (USD MILLION)
FIGURE 22 CHILE GASTRIC CANCER TREATMENT MARKET: BY STAGES, CAGR (2022-2029)
FIGURE 23 CHILE GASTRIC CANCER TREATMENT MARKET: BY STAGES, LIFELINE CURVE
FIGURE 24 CHILE GASTRIC CANCER TREATMENT MARKET: BY TREATMENT, 2021
FIGURE 25 CHILE GASTRIC CANCER TREATMENT MARKET: BY TREATMENT, 2020-2029 (USD MILLION)
FIGURE 26 CHILE GASTRIC CANCER TREATMENT MARKET: BY TREATMENT, CAGR (2022-2029)
FIGURE 27 CHILE GASTRIC CANCER TREATMENT MARKET: BY TREATMENT, LIFELINE CURVE
FIGURE 28 CHILE GASTRIC CANCER TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, 2021
FIGURE 29 CHILE GASTRIC CANCER TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
FIGURE 30 CHILE GASTRIC CANCER TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2022-2029)
FIGURE 31 CHILE GASTRIC CANCER TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE
FIGURE 32 CHILE GASTRIC CANCER TREATMENT MARKET: BY END USERS 2021
FIGURE 33 CHILE GASTRIC CANCER TREATMENT MARKET: BY END USERS, 2020-2029 (USD MILLION)
FIGURE 34 CHILE GASTRIC CANCER TREATMENT MARKET: BY END USERS, CAGR (2022-2029)
FIGURE 35 CHILE GASTRIC CANCER TREATMENT MARKET: BY END USERS, LIFELINE CURVE
FIGURE 36 CHILE GASTRIC CANCER TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2021
FIGURE 37 CHILE GASTRIC CANCER TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
FIGURE 38 CHILE GASTRIC CANCER TREATMENT MARKET: BY DISTRIBUTION CHANNEL, CAGR (2022-2029)
FIGURE 39 CHILE GASTRIC CANCER TREATMENT MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 40 CHILE GASTRIC CANCER TREATMENT MARKET: COMPANY SHARE 2021 (%)
研究方法
Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.
The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.
可定制
Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.